Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (299)	8/5/2003 10:30:23 PM
From: Madharry	Read Replies (1) of 824

listening to the conference call now- it sounds like the valve patients were only 10-12% of the total population sample. Seems very strange to me that on a statistical basis such a small percentage would skew the endpoint for the whole group unless the events are much higher proportionately in that group say 40% in the valve vs 10% in the nonvalve group. It would be interesting to hear from someone who actually designed some of these trials and see if they can make some sense of this. It also unclear to me whether they are continuing the trial and whether they are planning to present data to the fda on events after 180 days. Sure looks to me though based on this information that if i were getting cabg and a valve operation i would want to be given this drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next